Paradigm shift in oncology: Targeting the immune system rather than cancer cells

Mutagenesis

Volumn 30, Issue 2, 2015, Pages 205-211

  Shekarian, Tala ^a   Valsesia Wittmann, Sandrine ^b   Caux, Christophe ^a   Marabelle, Aurélien ^a,b  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMATINIB; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; PATTERN RECOGNITION RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; METASTATIC MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; NEOPLASMS;

EID: 84930705241     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/geu073     Document Type: Review

References (63)

1. Peyrilhe, B. (1773) Dissertatio academica de cancro. Acad. Sci. Humanio-rum Litt. Artium Lugdunensis.
2. Bland, C. S. (1981) The Halsted mastectomy: present illness and past history. West. J. Med., 134, 549-555.
3. Foray, N. (2013) Victor Despeignes (1866-1937): How a hygienist became the frst radiation oncologist. Cancer Radiother., 17, 244-254.
4. DeVita, V. T. and Chu, E. (2008) A history of cancer chemotherapy. Cancer Res., 68, 8643-8653.
5. Goodman, L. S. and Wintrobe, M. M. (1946) Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and Tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J. Am. Med. Assoc., 132, 126-132.
6. Mayer, E. L. (2013) Early and late long-term effects of adjuvant chemotherapy. Am. Soc. Clin. Oncol. Educ. Book., 2013, 9-14.
7. Gambacorti-Passerini, C. (2008) Part I: Milestones in personalised medi-cine-imatinib. Lancet Oncol., 9, 600.
8. Shaw, A. T., Hsu, P. P., Awad, M. M. and Engelman, J. A. (2013) Tyrosine kinase gene rearrangements in epithelial malignancies. Nat. Rev. Cancer., 13, 772-787.
9. Advani, R. H., Buggy, J. J., Sharman, J. P. et al. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has signifcant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol., 31, 88-94.
10. Fialkow, P. J. (1979) Clonal origin of human tumors. Annu. Rev. Med., 30, 135-143.
11. Campbell, P. J., Yachida, S., Mudie, L. J. et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 1109-1113.
12. Greaves, M. and Maley, C. C. (2012) Clonal evolution in cancer. Nature, 481, 306-313.
13. Green, M. R., Gentles, A. J., Nair, R. V. et al. (2013) Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood, 121, 1604-1611.
14. Gerlinger, M., Rowan, A. J., Horswell, S. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 366, 883-892.
15. Chapman, P. B., Hauschild, A., Robert, C. et al.; BRIM-3 Study Group. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 364, 2507-2516.
16. Rudin, C. M., Hann, C. L., Laterra, J. et al. (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med., 361, 1173-1178.
17. Awad, M. M., Katayama, R., McTigue, M. et al. (2013) Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med., 368, 2395-2401.
18. + T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood, 114, 4477-4485.
19. Davis, T. A., Czerwinski, D. K. and Levy, R. (1999) Therapy of B-cell lym-phoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res., 5, 611-615.
20. Busch, W. (1868) Aus der sitzung der medicinischen. Berliner Klin. Wochenschrift, 5, 137.
21. Coley, W. B. (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci., 105, 487-510.
22. Lesterhuis, W. J., Haanen, J. B. and Punt, C. J. (2011) Cancer immuno-therapy-revisited. Nat. Rev. Drug Discov., 10, 591-600.
23. Bennett, C. L., Christie, J., Ramsdell, F. et al. (2001) The immune dys-regulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet., 27, 20-21.
24. Wildin, R. S., Ramsdell, F., Peake, J. et al. (2001) X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet., 27, 18-20.
25. Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A. et al. (2001) Disruption of a new forkhead/winged-helix protein, scurfn, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet., 27, 68-73.
26. Ochs, H. D., Ziegler, S. F. and Torgerson, T. R. (2005) FOXP3 acts as a rheostat of the immune response. Immunol. Rev., 203, 156-164.
27. Colombo, M. P. and Piconese, S. (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer, 7, 880-887.
28. + Treg. Immunobiology, 214, 291-302.
29. + regulatory T cells in cancer patients. Blood, 107, 2409-2414.
30. Jensen, H. K., Donskov, F., Nordsmark, M., Marcussen, N. and von der Maase, H. (2009) Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin. Cancer Res., 15, 1052-1058.
31. van der Vliet, H. J., van der Vliet, H. J., Koon, H. B. et al. (2007) Effects of the administration of high-dose interleukin-2 on immunoregula-tory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res., 13, 2100-2108.
32. Trinchieri, G. (2010) Type I interferon: friend or foe? J. Exp. Med., 207, 2053-2063.
33. Ménétrier-Caux, C., Gobert, M. and Caux, C. (2009) Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res., 69, 7895-7898.
34. Fridman, W. H., Pagès, F., Sautès-Fridman, C. and Galon, J. (2012) The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer, 12, 298-306.
35. Paulos, C. M., Kaiser, A., Wrzesinski, C. et al. (2007) Toll-like receptors in tumor immunotherapy. Clin. Cancer Res., 13, 5280-5289.
36. Miller, R. A., Maloney, D. G., Warnke, R. and Levy, R. (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med., 306, 517-522.
37. Brody, J., Kohrt, H., Marabelle, A. and Levy, R. (2011) Active and passive immunotherapy for lymphoma: proving principles and improving results. J. Clin. Oncol., 29, 1864-1875.
38. Mellman, I., Coukos, G. and Dranoff, G. (2011) Cancer immunotherapy comes of age. Nature, 480, 480-489.
39. Topalian, S. L., Weiner, G. J. and Pardoll, D. M. (2011) Cancer immuno-therapy comes of age. J. Clin. Oncol., 29, 4828-4836.
40. Hodi, F. S. S., O'Day, S. J. S. J., McDermott, D. F. D. F. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 363, 711-723.
41. Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 366, 2443-2454.
42. Wolchok, J. D., Kluger, H., Callahan, M. K. et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 369, 122-133.
43. Galluzzi, L., Vitale, I., Abrams, J. M. et al. (2012) Molecular defni-tions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ., 19, 107-120.
44. Galluzzi, L., Senovilla, L., Zitvogel, L. and Kroemer, G. (2012) The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Dis-cov., 11, 215-233.
45. Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L. (2013) Immunogenic cell death in cancer therapy. Annu. Rev. Immunol., 31, 51-72.
46. Balachandran, V. P., Cavnar, M. J., Zeng, S. et al. (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med., 17, 1094-1100.
47. Hantschel, O., Rix, U., Schmidt, U. et al. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl Acad. Sci. USA, 104, 13283-13288.
48. Yang, Y., Liu, C., Peng, W., Lizée, G., Overwijk, W. W., Liu, Y., Woodman, S. E. and Hwu, P. (2012) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood, 120, 4533-4543.
49. Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R. and Fu, Y. X. (2014) Irradiation and anti-PD-L1 treatment syn-ergistically promote antitumor immunity in mice. J. Clin. Invest., 124, 687-695.
50. Marabelle, A. and Caux, C. (2012) Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. Blood, 120, 4454-4455.
51. Goutagny, N., Estornes, Y., Hasan, U., Lebecque, S. and Caux, C. (2012) Targeting pattern recognition receptors in cancer immunotherapy. Target. Oncol., 7, 29-54.
52. Krieg, A. M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol., 20, 709-760.
53. Postow, M. A., Callahan, M. K., Barker, C. A. et al. (2012) Immuno-logic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med., 366, 925-931.
54. Hiniker, S. M., Chen, D. S. and Knox, S. J. (2012) Abscopal effect in a patient with melanoma. N. Engl. J. Med., 366, 2035; author reply 2035-2035; author reply 2036.
55. Brody, J. D., Ai, W. Z., Czerwinski, D. K. et al. (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol., 28, 4324-4332.
56. Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. M. and Levy, R. (2007) Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol., 179, 2493-2500.
57. Houot, R. and Levy, R. (2009) T-cell modulation combined with intra-tumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood, 113, 3546-3552.
58. Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G. and Brogdon, J. L. (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med., 210, 1685-1693.
59. Simpson, T. R., Li, F., Montalvo-Ortiz, W. et al. (2013) Fc-dependent depletion of tumor-infltrating regulatory T cells co-defnes the effcacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med., 210, 1695-1710.
60. Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srini-vasan, M. and Korman, A. J. (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res., 1, 32-42.
61. Marabelle, A., Kohrt, H., Sagiv-Barf, I. et al. (2013) Depleting tumor-specifc Tregs at a single site eradicates disseminated tumors. J. Clin. Invest., 123, 2447-2463.
62. + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res., 19, 5381-5389.
63. Marabelle, A., Kohrt, H., Caux, C. and Levy, R. (2014) Intratumoral immunization: a new paradigm for cancer therapy. Clin. Cancer Res., 20, 1747-1756.